A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer

• DOI: 10.1126/scitranslmed.aad0293
• Publication Date: 2016-01-06T19:27:58Z
• Authors: Melodi Javid Whitley; Diana M. Cardona; Alexander L. Laza...; Ivan Spasojevic; Jorge M. Ferrer; Joan Cahill; Chang-Lung Lee; Matija Snuderl; Dan G. Blazer; E. Shelley Hwang; Rachel A. Greenup; Paul J. Mosca; Jeffrey K. Mito; Kyle C. Cuneo; Nicole A. Larrier; Erin K. O’Reilly; Richard F. Riedel; William C. Eward; David B. Strasfeld; Dai Fukumura; Rakesh K. Jain; W. David Lee; Linda G. Griffith; Moungi G. Bawendi; David G. Kirsch; Brian E. Brigman
• Keywords: Diagnostic Imaging; 610; Breast Neoplasms; Sarcoma; 3. Good health; Disease Models, Animal; Mice; 03 medical and health sciences; 0302 clinical medicine; Neoplasms; Injections, Intravenous; Metabolome; Animals; Humans; Female; Tissue Distribution; Fluorescent Dyes; Peptide Hydrolases

A first-in-human phase 1 clinical trial of the PEGylated protease-activated fluorescent probe, LUM015, enables tumor imaging at a safe and tolerable dose in humans.